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Abstract
Background: Cardiopulmonary resuscitation after cardiac arrest initiates a whole-body ischemia-reperfusion injury, which may activate the innate
immune system, including the complement system. We hypothesized that complement activation and subsequent release of soluble endothelial
activation markers were associated with cerebral outcome including death.
Methods: Outcome was assessed at six months and defined by cerebral performance category scale (12; good outcome, 35; poor outcome
including death) in 232 resuscitated out-of-hospital cardiac arrest patients. Plasma samples obtained at admission and day three were analysed for
complement activation products C3bc, the soluble terminal complement complex (sC5b-9), and soluble CD14. Endothelial cell activation was measured
by soluble markers syndecan-1, sE-selectin, thrombomodulin, and vascular cell adhesion molecule.
Results: Forty-nine percent of the patients had good outcome. C3bc and sC5b-9 were significantly higher at admission compared to day three
(p < 0.001 for both) and in patients with poor compared to good outcome (p = 0.03 and p < 0.001, respectively). Unadjusted, higher sC5b-9 at admission
was associated with poor outcome (odds ratio 1.08 (95% CI 1.011.14), p = 0.024). Adjusted, sC5b-9 was still associated with outcome, but the
association became non-significant when time to return-of-spontaneous-circulation above 25 min was included as a covariate. Endothelial cell
activation markers increased from admission to day three, but only sE-selectin and thrombomodulin were significantly higher in patients with poor versus
good outcome (p = 0.004 and p = 0.03, respectively) and correlated to sCD14 and sC5b-9/C3bc, respectively.
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Conclusion: Complement system activation, reflected by sC5b-9 at admission, leading to subsequent endothelial cell activation, was associated with
poor outcome in out-of-hospital cardiac arrest patients.
Keywords: Out-of-hospital cardiac arrest, Outcome, SC5b-9 protein complex, Cardiopulmonary resuscitation, Return of spontaneous circulation,
Immune system, Endothelial cells
Introduction
Out-of-hospital cardiac arrest (OHCA) remains an important public
health matter with a high mortality rate and is the third leading cause of
death in Europe.1 After successful resuscitation, the main reason for
mortality and morbidity is the duration of hypoxia and a whole-body
ischemia/reperfusion injury.2 The brain is most susceptible to this
reperfusion injury,3 and two-thirds of hospital deaths are due to the
neurological injury,4
The pathophysiology of ischemia/reperfusion injury is very
complex with a plethora of players. Cardiopulmonary resuscitation
(CPR) initiated reperfusion triggers the innate immune system by
danger agents acting as ligands for pattern recognition molecules of
the various branches of the innate immunity, including the comple-
ment system.5,6 This induces a secondary and broad-acting systemic
inflammatory response which, when over-activated or dysregulated,
leads to tissue damage, organ failure and in worst case to death.7
Complement is present in plasma and thus immediately activated
upon injury through the classical, lectin, or alternative pathway. All
three pathways converge at the level of C3, which gets cleaved and
forms a protease that cleaves C5 leading to the formation of the
terminal complement complex. The terminal complement complex is
either incorporated in cellular membranes, where it may result in lysis
and inflammation, or it is released as a soluble molecule (sC5b-9) to
the fluid phase.8 All C3 and C5 derived complement activation
products, including the anaphylatoxins C3a and C5a, can activate
endothelial cells.
The aim of the present study was to investigate if complement
activation with subsequent endothelial cell activation as part of the
initial ischemia/reperfusion injury was associated with poor cerebral
outcome and death in patients resuscitated after OHCA.
Material and methods
The present study is a planned sub-study of the prospective
observational Norwegian Cardio-Respiratory Arrest Study (NOR-
CAST, NCT01239420).9 The aim of NORCAST was to assess the
ability of currently recommended diagnostic tools to identify patients
with a poor prognosis. Importantly, results of prognostic tests were
blinded to clinicians to avoid hasty withdrawal decisions and self-
fulfilling prophecies. The design and patient population in NORCAST
has been previously described in detail.9 Briefly, 259 comatose adult
OHCA patients admitted to Oslo University Hospital Ullevål were
included between October 1st, 2010 and January 30th, 2014. Post-
resuscitation care was performed according to local standard
procedures including targeted temperature management to 33 C
(TTM33) for 24 h and immediate coronary angiography with
subsequent percutaneous coronary intervention, if a cardiac cause
was suspected.9 Hypoxic cause of cardiac arrest was defined as a
non-cardiac cause of the arrest, where hypoxia of different reasons
resulted in unresponsiveness, absence of breathing and loss of heart
function. The Sequential Organ Failure Assessment (SOFA score)
was performed to assess the extent of a patient's organ failure within
the first 24 h of admission. Neurological outcome at 6 months was
assessed by Neurology specialists who were blinded to all clinical and
paraclinical scores during hospital admission and well acquainted with
Cerebral Performance Category (CPC, 12 good outcome, 35 poor
outcome with 5 including death) scoring. The examination on which
CPC scoring was based consisted of structured neurological and
cognitive examination as well as queries of functional level to patients
and next-of-kin. For complement activation markers, the upper
reference limit for each assay was set to the 95th percentile of a
healthy reference population consisting of 20 female and 20 male
blood donors without cardiovascular or autoimmune diseases.10
Upper reference limit of sC5b-9 is >0.7 complement activation units
(CAU)/mL and for C3bc >9 CAU/mL.10 For endothelial markers such
international reference limit do not exist and venous EDTA-blood
obtained from twelve healthy volunteers with a close to similar age
(median 59 years, interquartile range 5168 years) and gender
distribution (7 female: 5 male) compared to the study population was
used as control.
Blood sampling protocol
At admission (before initiation of TTM33) and after 72 h (after
rewarming), peripheral venous blood was obtained in ethylenedia-
minetetraacetic acid (EDTA) vacutainer tubes (BD, Plymouth, UK).
Samples were immediately kept on crushed iced and centrifuged
within 30 min at 2500 g for 20 min at 4 C. Plasma was collected and
stored at 80 C until analyses.
Complement activation markers
Complement activation products, C3bc (common for classical, lectin
and alternative pathways) and sC5b-9 (soluble terminal complement
complex), were measured by in-house enzyme-linked immunosor-
bent assays (ELISA) which has previously been described11,12 and
later modified according to the protocol presented in Ref. 10.
Endothelial activation markers and sCD14
Soluble endothelial activation markers syndecan-1, sE-selectin
(sCD62E), thrombomodulin (sTM), vascular cell adhesion molecule
1(sVCAM-1) and sCD14 were measured by DuoSet ELISA (R&D
Systems, Minneapolis, MN) in EDTA plasma.
Ethics and data management
The Regional Committee for Medical Research Ethics of South-
Eastern Norway approved NORCAST (Approval number REK S-O/A -
2010/1116a). Ethics and study management have been previously
reported.9Written informed consent was obtained from close relatives
or guardians within 24 h after hospitalization and from all patients
regaining consciousness and decision-making capacity within six
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months. Clinical, biochemical and outcome data were prospectively
collected from medical records, questionnaires, and paramedic
records as presented in the Utstein criteria.13 Blood samples from
healthy donors were collected into a biobank approved by the
Regional Ethical Committee (REK S-04114).
Statistical analysis
Data were presented as medians, 25th75th percentile, or frequen-
cies and percentages, as appropriate. Patients with good and poor
outcome were compared by MannWhitney U test for continuous and
x2-test or Fisher’s exact test for categorical data. The difference in
complement or endothelial activation between CPC groups was
assessed by MannWhitney U test. KruskalWallis test was used for
comparison of more than two groups. Bonferroni correction was
applied to correct for multiple testing. The Wilcoxon signed-rank
paired test was used to compare the complement and endothelial
activation at admission and day three. Associations between cerebral
outcome and SOFA score, time from cardiac arrest-to-return-of-
spontaneous circulation (time-to-ROSC), cardiac arrest (unwitnessed
vs. witnessed), initial rhythm (shockable vs. non-shockable), bystand-
er CPR (yes vs. no), and cause of cardiac arrest were assessed by
unadjusted and adjusted (multivariable) logistic regression model. To
assess whether sC5b-9 and C3bc at admission was associated with
the odds for poor outcome separately as well as combined,
unadjusted logistic regression models were estimated. The models
were further adjusted for SOFA score, time-to-ROSC, and cause of
cardiac arrest. Interactions between sC5b-9 and time-to-ROSC, and
between C3bc and time-to-ROSC were included into the adjusted
model if significant. The results of logistic regression models were
presented as odds ratios (ORs) with the corresponding 95%
confidence intervals (CIs) and p-values. The regression coefficients
and standard errors (SE) were presented for the variables included
into the interaction term. For easier interpretation, the interactions
were illustrated graphically. To assess how well the sC5b-9 and C3bc
distinguishes between those with good and poor outcome, the area
under the characteristic (ROC) curve with the corresponding 95% CI
was calculated. The logistic regression models were estimated to
assess the association between the CPC score and sC5b-9 at
admission adjusted for endothelial markers Syndecan-1, E-selectin,
Thrombomodulin, and VCAM, and CD14 measured at day three, one
at a time. Also, the model combining all endothelial markers and CD14
was estimated. The models were adjusted for SOFA score, time-to-
return-of-spontaneous circulation (time-to-ROSC), and cause of
cardiac arrest. Area under the ROC curve calculated for the
unadjusted and each adjusted model was compared. Correlation
between complement and endothelial activation markers was
assessed using Spearman’s rank test. Results with p-values <0.05
were regarded as significant. Statistical analyses were performed in
Statistical Package for the Social Sciences (SPSS) software (version
26, IBM, Armonk, NY), Stata (version 16.0, StataCorp, College
Station, TX), SAS (version 9.4, SAS Institute, Cary, NC) and
GraphPad Prism (version 8, GraphPad Software, San Diego, CA).
Results
Out of 259 successfully resuscitated patients after OHCA, 232 were
included into the study (Fig. 1). Median age was 63 (5469), 83%
were male, and 82% had cardiac cause of arrest (Table 1). Outcome
defined as best CPC score within six months after OHCA, was poor for
49% and good for 51% of patients with significant differences in time-
to-ROSC and SOFA score at admission (Table 1). Clinical variables
significantly associated with poor outcome in adjusted logistic
regression analysis were non-shockable initial cardiac arrest rhythm,
longer time-to-ROSC and higher overall organ dysfunction during the
first 24 h after admission (Suppl. Table 1). Unwitnessed cardiac arrest
was associated with outcome in unadjusted logistic regression model
only, while performance of bystander CPR was not significantly
associated with outcome (Suppl. Table 1).
Complement activation products
C3bc and sC5b-9 were markedly higher compared to upper reference
limit in all patients (n = 232) both at admission and day three (Fig. 2A,
B). C3bc and sC5b-9 were both significantly higher at admission
compared to day three. Patients with poor outcome had significantly
higher levels of C3bc and sC5b-9 at admission compared to patients
with good cerebral outcome (Fig. 2A, B).
In unadjusted models, higher sC5b-9 at admission was associated
with poor outcome (OR 1.08, 95% CI (1.011.14), p = 0.02, Suppl.
Table 2), while C3bc was not (Suppl. Table 3). The area under the
ROC curve (AUC) was 0.65 95% CI (0.57; 0.72) for sC5b-9 and 0.57
(0.49; 0.65) for C3bc. There was no additive effect on the ROC curve
by combining sC5b-9 and C3bc (AUC 0.66 (0.58; 0.73)). Longer time-
to-ROSC and higher SOFA scores at admission were also associated
with poor outcome (OR 1.06 (1.051.09), p < 0.001 and OR 1.23
(1.061.43), p = 0.006, respectively, Suppl. Table 2). Interaction
between sC5b-9 and time-to-ROSC was significant in an adjusted
model (p = 0.015, Suppl. Table 2). Post hoc analysis of the interaction
term showed that odds for poor outcome were increasing with
increasing values of sC5b-9 when time-to-ROSC was below 30 min,
while odds for poor outcome were dependent on time-to-ROSC alone
at 30 min and longer (Suppl. Table 2, Fig. 3). There was no significant
interaction between C3bc and time-to-ROSC in an unadjusted model,
Admit ted  to hospitalafter out-of-hospital cardiac arrest
(n=259 )
Included with avail able clinical data
(n= 243) 
Included with av ail able samples at admis sion(n=232 )and 
admis sion + day  3  (n=192 ) 
No blood collected at  admis sion  and day 3 (n=3)
No blood collected at  admis sion  (n=8)
No blood collected at  day 3 (n=40)
TTM protocol  disconti nued , earlydeath, early 
awakening(n=16) 
Fig. 1 – Flow chart of patient population in this study.
Enrolment in study and exclusions, availability of clinical
data and blood samples at each time point. TTM; target
temperature management.
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and C3bc alone was not associated with outcome (Suppl. Table 3).
Hypoxia as the cause of cardiac arrest increased the odds for poor
outcome, with increased levels of sC5b-9 and C3bc at admission in
comparison to acute myocardial infarction (OR 6.78 (1.9024.16),
p = 0.003, and OR 5.97 (1.7520.36), p = 0.004, respectively, Suppl.
Tables 2 and 3).
sCD14
sCD14, a co-receptor of TLR, was significantly higher in cardiac arrest
patients (n = 192) compared to healthy controls and significantly
higher at day three compared to admission (Suppl. Fig. 1). However,
sCD14 was not associated with outcome alone or in adjusted models
(Suppl. Table 4).
Markers of endothelial activation and damage
Glycocalyx damage marker sSyndecan-1 was higher in OHCA
patients (n = 192) compared to healthy controls at admission and day
three (Fig. 4A). It was significantly higher at admission compared to
day three in OHCA patients (Fig. 4A). Markers of endothelial activation
sE-selectin, sVCAM-1 and sTM were consistently higher in OHCA
patients and concentrations at day three were significantly increased
compared to admission (Fig. 4BD). Among the four markers, only
sE-selectin and sTM were significantly higher in patients with poor
outcome compared to patients with good outcome (Fig. 5A, B). C3bc
correlated significantly with sSyndecan-1 and sTM at admission
(R = 0.26, p < 0.001 and R=0.17, p = 0.02, respectively) and day three
(R = 0.19, p = 0.007 and R=0.2, p = 0.007, respectively, Suppl. Fig. 2).
Likewise, sC5b-9 correlated significantly with sSyndecan-1 and sTM
at admission (R = 0.25, p < 0.001 and R=0.23, p = 0.001, respectively)
and at day three (R=0.16, p = 0.03 and R = 0.23, p = 0.002, Suppl.
Fig. 2). sCD14 was significantly correlated with sE-selectin at day
three (R = 0.44, p < 0.001). No other important correlations were
observed (Suppl. Fig. 2). sE-selectin was the only endothelial
parameter significantly associated with outcome in an unadjusted
model (OR 1.02 [1.001.05], p = 0.038), but did not improve the
discriminative ability of the model with only sC5b-9 (Suppl. Table 4).
Adjustment did not improve the discriminative ability of sC5b-9 in
combination with endothelial markers except for E-selectin with
additive effect on the ROC curve when sC5b-9 was combined with sE-
selectin (AUC 0.79 (0.720.85), p = 0.047, Suppl. Tables 4 and 5).
Discussion
A whole-body inflammatory reaction follows resuscitation after OHCA.
In the present study, we show that initial strong activation of the
complement system, in particular reflected by the terminal pathway
activation product sC5b-9, was associated with poor long-term
outcome. Following the initial rapid complement activation, endothe-
lial activation occurred after admission. While the endothelial damage
marker Syndecan-1 peaked at admission, all other measured markers
of endothelial activation showed highest level at day three in contrast
to complement activation, which then had markedly declined.
Complement activation
Complement activation at admission was associated with cerebral
outcome. Complement has been shown to get activated immediately
after initiation of resuscitation in OHCA patients with a swift decline
after ROSC.14 This might be due to release of damage associated
molecular patterns (DAMPs) from injured cells followed by a chain of
injurious events15 leading to activation of complement signalling
pathways, in particular the lectin pathway.16 While the aforemen-
tioned study showed no relation of lectin pathway activation and
outcome, this study confirms that the end-product of complement
system activation sC5b-9 is associated with poor outcome. TTM33
Table 1 – Demographics and clinical characteristics at admission.
Total (n = 232) Good outcome (CPC 12)
(n = 118)
Poor outcome (CPC 35)
(n = 114)
p-value
Age (years) 63 (5470) 62 (5469) 64 (5571) 0.3a
Sex 0.5b
Female 39 (17) 14 (36) 25 (64)
Male 193 (83) 104 (54) 89 (46)
Cause of cardiac arrest (CA)
Acute myocardial infarction 89 (38) 48(54) 41 (46) 0.5b
Chronic cardiac disease 71 (31) 40 (56) 31 (44) 0.3b
Arrythmia (VF) 29 (13) 18 (62) 11 (38) 0.2b
Hypoxia induced CA 31 (13) 9 (29) 22 (71) 0.01b
Other causes 5 (2) 2 (40) 3(60) 0.7c
Unknown 7 (3) 1 (14) 6 (86) 0.6c
Survivors 123 (53) 114 (93) 9 (7) <0.001b
Scores at admission
SOFA score 11 (9.512) 10 (912) 11 (1012) <0.001a
Time-to-ROSC (min) 25 (1633) 19 (1228) 30 (2440) <0.001a
Data presented as median (25th75th percentile) or n (%). Cerebral outcome is best CPC within 6 months after cardiac arrest. CPC; cerebral performance
category, VF; ventricular fibrillation, CA; cardiac arrest, SOFA; Sequential Organ Failure Assessment, Time-to-ROSC; time to return of spontaneous circulation,
min; minutes.
a MannWhitney U test.
b x2-test or
c Fisher’s exact test.
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treatment of OHCA patients leads to suppression of complement
activation with return to levels above reference limit after rewarming17
while one study reports that TTM33 lead to reduction of the regulatory
protein Map19 of the complement lectin pathway compared to
TTM36.18 All patients in this study were treated with TTM33 and it
might thus be speculated that the initial complement activation is of
special importance for outcome in OHCA patients. In line with this are
findings that the degree of complement activation correlates with the
severity of heart failure in patients developing cardiogenic shock after
acute myocardial infarction.19 Furthermore, blockade of C5 reduced
infarct size and improved cardiac function in an experimental porcine
model of severe myocardial infarction.20
An important factor influencing the reperfusion injury and degree of
neurological injury is the duration of hypoxia i.e., the time-to-ROSC.21
As in previous studies, we also verified an association between time-
to-ROSC and poor cerebral outcome.22 We add that for the same
time-to-ROSC, odds for poor outcome increased with increasing
levels of sC5b-9, suggesting that increased complement activation
per se had an effect on outcome and might be an effect-modifier. The
effect of association between sC5b-9 and outcome was absent in
patients with time-to-ROSC 30 min, indicating that the impact of
inflammation on cerebral outcome may be reduced when time-to-
ROSC is long and ischemic brain damage becomes the only decisive
factor. Despite the association between sC5b-9 and poor outcome,
complement activation cannot be used as a decisive prognostic
marker, given the large inter-patient variations of absolute values,
which were in this study almost all above an internationally accepted
upper reference limit.10 However, complement inhibition in OHCA
patients might be explored in further studies as inhibition of C5 has
been shown to reduce ischemia/reperfusion injury in general, and our
data on sC5b-9 support this hypothesis.
sCD14
sCD14 is a multifunctional molecule, which recognises and binds
endogenous and exogenous danger signals.23 It is also a co-factor for
several TLRs which are mainly expressed by monocytes and
macrophages. In the present study, sCD14 was increased upon
admission and highest on day three, suggesting a maintained release,
which might be due to shedding of membrane-bound CD14 protein or
secretion via intracellular vesicles by inflammatory cells.24 The
prolonged release of sCD14 may indicate prolonged activation of the
immune system which is in agreement with the pattern of complement
and endothelial activation.
Endothelial activation
The endothelium is an active component of innate immunity. It gets
injured during ischemia/reperfusion injury,25 e.g. by complement. This
again leads to retrograde complement activation resulting in a vicious










































Admission Day 3 Admission Day 3
p<0.001
9
Fig. 2 – Patients (n = 232) with successful resuscitation
after out-of-hospital-cardiac-arrest. Plasma levels of
C3bc and sC5b-9 at admission (blue lines) were above
upper reference limit (line) in most of the patients,
significantly higher at admission compared to day three
(red lines) and higher in patients with poor compared to
good cerebral outcome (A, B).
Cerebral outcome was defined by cerebral performance
category (CPC) as good; CPC 12 and poor; CPC 35.
Data is shown as box plots with median as line and box
indicating 25th75th percentile and whiskers represent-
ing 10th90th percentiles. Wilcoxon signed-rank paired
test and non-paired MannWhitney U test.
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Fig. 3 – Interaction between sC5b-9 and time-to-ROSC is
associated with poor outcome. Increasing values of
sC5b-9 were associated with poor outcome when time-
to-ROSC was 25 min but not when time-to-ROSC was 30
min or higher (asterix). Odd ratios adjusted for cova-
riates SOFA, Time-to-ROSC and cause of cardiac arrest.
CAU; complement arbitrary unit, Time-to-ROSC; time-to-
return-of-spontaneous-circulation, SOFA; Sequential
Organ Failure Assessment.
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Syndecan-1 was the only endothelial marker that peaked on the
day of admission, which is in-line with previous findings describing
shedding of glycocalyx as an initial event in OHCA patients, where
Syndecan-1 is an integral part.27 While sSyndecan-1 correlated
significantly with complement activation, it was not associated with
outcome. Thus, our findings confirm results of a previous study in 163
comatose patients after OHCA, where sSyndecan-1 was not
associated with mortality,22 which may imply that sSyndecan-1 is
an endothelial damage marker, but not necessarily associated with
prolonged inflammatory reperfusion injury.
Complement system and endothelial cell activation have been
shown to correlate with systemic cytokine release and haemodynamic
status early post-cardiac arrest. The magnitude of this response has
been associated with the severity of this post-cardiac arrest
syndrome,5,8 independent on TTM.28 Likewise, endothelial activation
and damage markers have been shown to be independent of TTM,
except for sE-Selectin, which is lower in TTM36 treated patients.22
The present study confirms this previously observed pattern of
complement and endothelial activation and that endothelial activation
reflected by thrombomodulin is associated with outcome,22 although
individual correlations of single parameters are relatively weak. In a
study on 163 patients with one-time blood sampling within
approximately two hours after OHCA, Cox proportional-hazard
analyses found sE-selectin to be a univariate predictor of mortality.29
Our findings add that sE-selectin is associated with outcome, also
when assessed three days after OHCA. In addition, we show that sE-
selectin is correlated with sCD14 at day three after cardiac arrest and
not with the complement system, highlighting the multifactorial
pathogenesis of the post-cardiac arrest syndrome. Unfortunately,
due to large inter-patient variations seen in our and the aforemen-
tioned studies, thrombomodulin and sE-selectin are not reliable
prognostic markers. Especially sE-selectin levels are affected by
body-mass index.30 However, both sE-selectin and thrombomodulin
could be used in future clinical intervention studies assessing effect of
an intervention by reduction of these endothelial activation markers.
Dual inhibition of both the complement system and CD14 in post-
OHCA patients may be a general approach to attenuate the innate
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Fig. 4 – Patients (n = 192) with successful resuscitation
after out-of-hospital-cardiac-arrest and blood samples
both at admission and day three. Plasma levels of
sSyndecan-1 (A), sE-selectin (B), and sVCAM (C) were
significantly higher compared to healthy controls (black
lines) at admission (blue lines) and day three (red lines),
while sTM (D) was significantly higher at day three, only.
sSyndecan was significantly higher at admission com-
pared to day three, while sE-selectin, sVCAM and sTM
were higher at day three compared to admission. Data is
shown as box plots with median as line and box
indicating 25th75th percentile and whiskers repre-
senting 10th90th percentiles. Wilcoxon signed-rank






































Admission AdmissionDay 3 Day 3
Admission AdmissionDay 3 Day 3
Fig. 5 – sE-Selectin (A) and sTM (B) in patients (n = 192)
with successful resuscitation after out-of-hospital-car-
diac-arrest. In patients with poor cerebral outcome, sE-
selectin and sTM were significantly higher at day three
(red lines) compared to admission (blue lines).
Cerebral outcome was defined by cerebral performance
category (CPC) as good; CPC 12 and poor; CPC 35.
Data is shown as box plots with median as line and box
indicating 25th75th percentile and whiskers represent-
ing 10th90th percentiles. Wilcoxon signed-rank paired
test and non-paired MannWhitney U test. sTM;
sThrombomodulin.
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immune system including activation of endothelial cells, cytokine
storm, and adaptive immune system,31,32 and ought to be investigated
further.
Limitations
This was a post-hoc analysis of a single-center study, which limits
generalizability. Despite a rigorous sampling routine, blood was not
acquired from 40 patients at day three, decreasing power of
especially endothelial markers, which are known to be time-
sensitive and increase later than complement activation markers. All
patients were treated with the same TTM33 protocol reducing
generalization to internationally recommended post resuscitation
care, which includes TTM36. However, by focusing on TTM33,
confounders based on quality of care were minimized. Time-to-
ROSC is a pure quantitative parameter, and the quality of CPR,
which is a known predictor of outcome, was not assessed.33 This
could therefore impact on the data. As this is an observational study,
no cause-effect conclusions can be made, the study should thus be
regarded as hypothesis generating, and may facilitate design of
future studies investigating interventions in the immediate post-
cardiac arrest phase.
Conclusion
In comatose, resuscitated OHCA patients, activation of the comple-
ment system is present in the majority of patients at admission. In
particular, increased sC5b-9 was associated with poor outcome. The
whole-body inflammation included subsequent endothelial cell
activation and sCD14 release three days after OHCA.
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